caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines



November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011


Wednesday, February 28, 2007
MBP8298 moving along for those that are SPMS

2007-02-28 15:10:36

The first phase of testing
is done
and now those patients on placebo can carry on with the actual drug.
I wonder what that feels like when you find out you were on the placebo? Anyone
have that experience? Were you convinced you were actually on the drug? "Eligible
patients who have successfully completed the blinded, placebo controlled MAESTRO-01
trial may choose to receive MBP8298 on an un-blinded basis in MAESTRO-02 regardless
of whether they were previously on placebo or drug. The trial will primarily
evaluate the long-term safety of MBP8298. "Now that the first patients
who participated in our MAESTRO-01 pivotal trial have completed the study, we
are pleased to offer MBP8298 on an open-label basis," said Kevin Giese, President
and CEO of BioMS Medical. "We believe MBP8298 has the potential to become the
only safe and effective first line therapy for the treatment of secondary progressive
MS. While MAESTRO-01 was designed to evaluate the safety and efficacy of MBP8298,
MAESTRO-02 will provide additional important long-term safety and efficacy data
to support regulatory submissions."